Abstract
Ceftobiprole (BAL9141) is an investigational cephalosporin active against methicillin- and vancomycin-resistant staphylococci administered as a water-soluble prodrug, ceftobiprole medocaril (BAL5788). Using an immunocompetent murine pneumonia model of Haemophilus influenzae, Enterobacter cloacae, or extended-spectrum beta-lactamase (ESBL) nonproducing or producing Klebsiella pneumoniae pneumonia, we compared results of treatment with ceftobiprole medocaril (71 mg/kg, sc, qid), ceftriaxone (50 mg/kg, im, bid), or cefepime (50 mg/kg, ip, q.i.d.). Results were expressed as median and 25th to 75th percentile log10 colony forming units per gram of lung tissue. Ceftobiprole, ceftriaxone, and cefepime were each more active than was no treatment and were equally active for treatment of experimental H. influenzae, E. cloacae, or ESBL-nonproducing K. pneumoniae pneumonia. For ESBL-producing K. pneumoniae, no differences were detected between no treatment and treatment with ceftobiprole, ceftriaxone, or cefepime. Ceftobiprole is active against H. influenzae, E. cloacae, and ESBL-nonproducing K. pneumoniae in an immunocompetent experimental murine pneumonia model.
References
Jun 22, 1999·Postgraduate Medicine·J A Lee
Feb 22, 2001·Antimicrobial Agents and Chemotherapy·P HebeisenR L Then
Dec 26, 2001·Antimicrobial Agents and Chemotherapy·J M EntenzaP Moreillon
Dec 4, 2002·The Journal of Antimicrobial Chemotherapy·Ronald N JonesDouglas J Biedenbach
Oct 18, 2003·The Journal of Antimicrobial Chemotherapy·Bulent BozdoganPeter C Appelbaum
Feb 6, 2004·Diagnostic Microbiology and Infectious Disease·Nicolas C IssaRobin Patel
Mar 30, 2004·Antimicrobial Agents and Chemotherapy·E Azoulay-DupuisS Shapiro
Jun 25, 2004·Antimicrobial Agents and Chemotherapy·Anne Schmitt-HoffmannPéter Kovács
Feb 25, 2005·Antimicrobial Agents and Chemotherapy·Henry F Chambers
Apr 28, 2005·Antimicrobial Agents and Chemotherapy·Klaudia KosowskaPeter C Appelbaum
Citations
Jun 6, 2009·International Journal of Clinical Practice·R A SteinG M Ganea
Apr 18, 2007·Antimicrobial Agents and Chemotherapy·Cesar A AriasBarbara E Murray
Jun 27, 2007·Antimicrobial Agents and Chemotherapy·Anne Marie QueenanKaren Bush
Aug 5, 2008·Antimicrobial Agents and Chemotherapy·W A Craig, D R Andes
Apr 16, 2008·Antimicrobial Agents and Chemotherapy·Somvadee LaohavaleesonDavid P Nicolau
Nov 9, 2011·Antimicrobial Agents and Chemotherapy·A StuckiP Cottagnoud
Jan 1, 2010·Infection and Drug Resistance·César Bustos, Jose L Del Pozo
Jun 14, 2008·Clinical & Developmental Immunology·Natalia MiliotiErnesto Oviedo-Orta
Aug 15, 2014·Drugs·Yahiya Y Syed
Sep 9, 2009·Expert Review of Anti-infective Therapy·Patricia L Schirmer, Stanley C Deresinski
Mar 21, 2007·Expert Opinion on Investigational Drugs·Karen BushGary J Noel
Jan 25, 2007·Expert Opinion on Investigational Drugs·Garyphallia Poulakou, Helen Giamarellou
Jun 17, 2009·Expert Opinion on Pharmacotherapy·Ali El Solh
Apr 4, 2008·Diagnostic Microbiology and Infectious Disease·Stanley C Deresinski
Apr 4, 2008·Diagnostic Microbiology and Infectious Disease·Thomas P LodiseRonald N Jones
Nov 18, 2015·Future Microbiology·Thomas W L Scheeren
Apr 29, 2009·Pharmacotherapy·Céline Vidaillac, Michael J Rybak
Jul 2, 2009·Journal of Chemotherapy·S CorvecH Drugeon
Jul 4, 2007·The Journal of Antimicrobial Chemotherapy·Cesar A AriasBarbara E Murray
Nov 6, 2014·Jundishapur Journal of Microbiology·Fereshteh ShahcheraghiSeyed Mohsen Zahraei
Jan 30, 2015·Jundishapur Journal of Microbiology·Mojtaba MoosavianAmir Peymani
Mar 17, 2015·Jundishapur Journal of Microbiology·Ahmad Farajzadeh SheikhRaheleh Sheikhi